Bai et al. speculated the FGA could be a potential biomarker for forecasting relapse, monitoring minimal residual disease, and evaluating therapeutic response in adult acute lymphocytic leukemia patients [19], and several reports have described the involvement of FGA expression in malignant tumors, such as multiple myeloma, hepatocellular carcinoma, colorectal cancer, gastric cancer, and oral squamous cell carcinoma, as well as its role as a poor prognostic factor [20,21,22,23]. This evidence concerns the gene FGA and plasma cell myeloma.